Trial reportPsychiatric genetics2010
Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine.
Trial report in Psychiatric genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02634684 (Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Systematic reviews of the acute effects of amphetamine on working memory and other cognitive performances in healthy individuals, with a focus on the potential influence of personality traits.Human psychopharmacology · 2023Pooled it
- Does impulsivity change rate dependently following stimulant administration? A translational selective review and re-analysis.Psychopharmacology · 2016Pooled it
- Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults.Psychopharmacology · 2017Trial
- Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers.Journal of psychiatry & neuroscience : JPN · 2014Trial
- Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention.Experimental and clinical psychopharmacology · 2013Trial
- Candidate gene studies of a promising intermediate phenotype: failure to replicate.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.Psychopharmacology · 2013Trial
- Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa.PloS one · 2013Trial
- COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation.Journal of clinical psychopharmacology · 2012Trial
- Article
- Review
- The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder.Brain and behavior · 2020Article
- Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction.Addictive behaviors · 2019Article
- Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.Schizophrenia bulletin · 2017Article
- COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review.The pharmacogenomics journal · 2016Review
- Multivariate analysis of subjective responses to d-amphetamine in healthy volunteers finds novel genetic pathway associations.Psychopharmacology · 2015Article
- A review of pharmacogenetic studies of substance-related disorders.Drug and alcohol dependence · 2015Review
- Genetics and the placebo effect: the placebome.Trends in molecular medicine · 2015Review
- Amphetamine increases errors during episodic memory retrieval.Journal of clinical psychopharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveVariation in the catechol-O-methyltransferase (COMT) val(158)met polymorphism has been associated with executive cognition and working memory, presumably mediated by the prefrontal cortex. Here, we extend these observations by examining two measures of cognitive function, lapses in attention and visuo-spatial-motor speed of processing, in both the drug-free state and after administration of d-amphetamine.
methodsHealthy Caucasian male and female participants (n=161) participated in a double-blind, crossover design study where they received placebo or d-amphetamine (10 and 20 mg). The outcome measures included self-reported mood states, a simple reaction time task, and a task measuring visuo-spatial-motor speed of processing. We first evaluated whether the genotypic groups differed on any of the measures in the absence of drug administration, including a measure of personality. We then determined whether the genotypic groups differed in their responses to acute doses of d-amphetamine (10 or 20 mg).
resultsWe found that without drug, val/val and val/met carriers showed greater lapses in attention on the reaction time task than met/met carriers, but the genotypic groups did not differ on the visuo-spatial-motor speed of processing task. Val/val carriers scored higher on a personality measure of extraversion than val/met and met/met carriers. Compared with placebo, the lower dose of d-amphetamine (10 mg) improved lapses in attention and visuo-spatial-motor speed of processing in val/val carriers, and decreased lapses in attention in val/met carriers. The highest dose of d-amphetamine (20 mg) improved performance on lapses in attention and visuo-spatial-motor speed of processing tasks in both val/val and val/met carriers, but not in met/met carriers. None of the genotypic groups differed on mood states, either with or without drug administration.
conclusionThe results of this study extend earlier findings with the COMT genotypes to additional measures of cognition, and suggest that the presence of the val allele is associated with poorer performance and greater improvement with a stimulant drug. The results further suggest that this polymorphism does not affect the mood-altering effects of d-amphetamine, consistent with the preferential influence of COMT in cortical regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.